Slide 1: Abera Bioscience
Abera Bioscience The world leading mucosal vaccine company Maria Alriksson CEO, Abera Bioscience 2026
Slide 2: A disruptive technology to revolutionize the vaccine industry
A disruptive technology to revolutionize the vaccine industry Abera develops mucosal vaccine candidates based on our innovative and proprietary platform technologies Backed by large grants from Next step - from preclinical to Significant interest from big prominent organizations clinical stage compa
Slide 3: Pipeline of mucosal vaccine candidates
Pipeline of mucosal vaccine candidates Phase 1 to start autumn 2026
Slide 4: BERA platform – OMVs decorated with large amounts of antigen for new vaccine candidates
BERA platform – OMVs decorated with large amounts of antigen for new vaccine candidates Abera can decorate OMVs with large amounts of antigen of one or more varieties. The carrier of antigen enhances the immune response and antigen provides strong and broad protection. [1] + Disease specific antigen
Slide 5: Advantages with mucosal vaccines
Advantages with mucosal vaccines - multiple observed and inferred advantages Double protection Mucosal delivery with the BERA platform elicits both local (IgA) and systemic (IgG) protection, mimicking protection after natural transmission Broader protection Secretory IgA can exhibit cross-reactivity
Slide 6: A ready to use mucosal vaccine platform
A ready to use mucosal vaccine platform - immunogenic & safe, ready for industrial production Highly immunogenic No added adjuvant needed Safe in Tox study Cost-efficient and consistent production Analytical package validated First candidate ready to enter clinical phase
Slide 7: The “virus like” bacterial mucosal platform
The “virus like” bacterial mucosal platform - induce both local and systemic immune response Hinder colonization and viral load Prevent disease & transmission Strong mucosal immune response High IgA & T cell response Humoral systemic immune response Significant IgG titers Innate response Kicks in ea
Slide 8: Abera’s Serotype-independent Pneumococcal Vaccine
Abera’s Serotype-independent Pneumococcal Vaccine
Slide 9: The Challenge - Limitations of current pneumococcal vaccine paradigm
The Challenge - Limitations of current pneumococcal vaccine paradigm • Existing vaccines are all serotype specific Prevalence of invasive pneumococcal disease • Serotype replacement makes current vaccines only temporarily effective Example: When Prevnar 13 was introduces in Sweden the 13 serotypes a
Slide 10: Ab-01.12 - a broadly protective nasal vaccine
Ab-01.12 - a broadly protective nasal vaccine • Serotype-independent vaccine protecting against all serotypes, hinder serotype replacement Based on the OMV's decorated with conserved antigens (antigens presented among all variants)10 . Serotype prevalence differ extensively from region to region. A
Slide 11: Serotype-independent pneumococcal vaccine hinders colonization
Serotype-independent pneumococcal vaccine hinders colonization - prevents disease AND transmission Our vaccine is administered as a nasal spray, utilizing intranasal immunization to replicate natural immunological processes and trigger a mucosal immune response, specifically targeting the S. pneumon
Slide 12: Universal pneumococcal candidate induces humoral responses
IgA in mucosa for Antigen 1 (rat) Universal pneumococcal candidate induces humoral responses – Mucosal and systemic antibodies • OMV vaccine induces IgA in mucosa • IgG systemic antibodies • Significant Th17 responses Sustained antibody response over time Significant IgG response against the antigen
Slide 13: Progress towards clinic with early efficacy indications
Progress towards clinic with early efficacy indications Extensive pre-clinical program in collaboration with Radboud UMC, the Netherlands. Successful GLP tox study performed on vaccine with no toxicological findings noted. GMP batch produced and released from NorthX Biologics. Clinical phase 1 plann
Slide 14: Extensive market and valuable clinical candidates
Extensive market and valuable clinical candidates Market size GSK acquisition of Affinivax Vaxcyte market cap 13 In may 2022 GSK acquired Affinivax for $2.1b in Pneumococcal vaccine market Vaxcyte with a 24-valent PCV up-front payments plus $1.2b sales of $ 8.4b in pneumo vaccine candidate in in mil
Slide 15: Abera’s Intranasal Influenza Vaccine
Abera’s Intranasal Influenza Vaccine
Slide 16: Fast-to-adapt intranasal influenza vaccine
Fast-to-adapt intranasal influenza vaccine The challenge Abera’s solution High disease burden with estimated 1 billion Intranasal vaccine to hinder both disease and cases of seasonal influenza per year transmission 3-5 million sever cases[11] Fast production and easy strain adaption – Yearly adaptio
Slide 17: Promising results in first in vivo study
Promising results in first in vivo study - High IgG and IgA titers[13] - No disease symptoms in vaccinated mice[13] High systemic IgG antibody titers High mucosal IgA antibody titers Weight change after in both nose and lung virus challenge B I O S C I EN C E
Slide 18: Sustained antibody responses over time
Sustained antibody responses over time Significant and sustained IgG and IgA titers over time in longevity study (mice) [13] Local, nasal & bronchial, antibody Sustained systemic antibody levels (IgG) titers (IgA) still after 120 days B I O S C I EN C E
Slide 19: Vaccination reduce viral load
Vaccination reduce viral load - No detectable virus in nasal nor bronchial lavage in high dose group (mice) [13] Virus titers in nasal lavage Virus titers in bronchial lavage Confirming data in ferrets Available under CDA
Slide 20: Powder and liquid formulations works equal well
Powder and liquid formulations works equal well - Similar IgG and IgA data in rats for both formulations High local antibody levels (IgA) in nasal High systemic antibody levels (IgG) in lavage for both powder and liquid serum for both powder and liquid [Data on file] B I O S C I EN C E
Slide 21: Pipeline Projects
Pipeline Projects
Slide 22: Fast design & development of new candidates
Fast design & development of new candidates - enabling multiple discovery projects and rapid-response possibilities In advance of project 3 weeks 2-10 weeks 1 day 1-2 weeks Ready for testing! Stockpile of OMVs Antigen production Decoration of OMVs Purification & Quality control Abera’s OMVs are stab
Slide 23: Abera OMV stockpile - future pandemic preparedness
Abera OMV stockpile - future pandemic preparedness Abera's BERA platform offers significant advantages as a pandemic preparedness tool – validated for stockpiling of OMVs and enabling rapid development of vaccine candidates in weeks. The platform utilises affordable, simple production methods possib
Slide 24: A nasal COVID-19 vaccine candidate
A nasal COVID-19 vaccine candidate - Developed with Johns Hopkins University School of Medicine RBD BERA platform with OMVs decorated with the spike protein from SARS-Cov-2 Successful In vivo challenge study [14] - Reduction of viral load in lungs and mucosal fluids - Antigen-specific antibodies in
Slide 25: Chlamydia vaccine candidate
Chlamydia vaccine candidate - early promising results developed through Horizon grant Chlamydial infection, caused by Chlamydia trachomatis, is the most prevalent bacterial sexually transmitted infection. Over 3.2 million cases diagnosed 2021 No existing vaccine against Chlamydia on market Potential
Slide 26: ETEC vaccine candidate
ETEC vaccine candidate - promising start for broad diarrheal vaccine Diarrheal diseases account for over 1.7 million deaths each year and 800 000 of those are children. 1 in 9 child deaths worldwide is caused by diarrheal. Escherichia coli (ETEC) bacteria and Rotavirus are the most common causes but
Slide 27: About Abera
About Abera
Slide 28: Science-centric spin-out advancing to clinical stage company
Science-centric spin-out advancing to clinical stage company Strong IP portfolio and extensive pipeline with first clinical trials planned Abera is a innovative vaccine platform company with strong scientific background. It was founded 2012 as a spin- off from Stockholm University and Vrije Universi
Slide 29: Abera Bioscience from lab bench to today
Abera Bioscience from lab bench to today Tox studies for Phase 1 Clinical Abera receives several Ab-01.12 Trial for Ab-01.12 First patent for research grants & develops platform and first PoC for Up-scaling of production vaccine platform GMP production pneumococcal process for Ab-01.12 submitted of
Slide 30: Major development has been funded through research projects
Major development has been funded through research projects 2012 & 2015: SWT, Dutch government Direct grant of SEK 4.1 million to Abera for the development of the platform 2020: Covid-19 Indirect grants through several collaborative projects in early phase 2012: EU, Additec Large project within Tube
Slide 31: Experienced and versatile team
Experienced and versatile team MSc. Maria Alriksson PhD. Mats Lundgren AssProf. Joen Luirink Prof. Marien de Jonge MSc. Anders Ericson CEO CSO CTO Radboud UMC Executive Chairman MSc. Ann-Christin Magnusson PhD. Bart van den Berg PhD. Calle Niemi PhD. Jessica Pettersson PhD. Lucille van Beek PhD. Emm
Slide 32: Business oriented Board of Directors with diverse expertise
Business oriented Board of World-leading experts in active Directors with diverse expertise Scientific Advisory Board Anders Ericson Dr Camille Lochte Dr Mats Wahlström Chairman of the board Inserm, Inventor of Intranasal Bordetella Experienced investor and former director Former CEO Abera. Professi
Slide 33: Maria Alriksson, CEO, Abera Bioscience
Maria Alriksson CEO, Abera Bioscience +46 70 433 0449 Maria.Alriksson@aberabio.com